Drug price poses dilemma

The government’s plan to evaluate the economic effectiveness of existing insurance-covered medicines has posed a new dilemma for those who are involved in drug prices in pharmaceutical firms.

“The government’s pressure to lower drug costs through a variety of approaches is a big headache to us,” a company official said.

“The problem is that there is little room for us to cope with the dr...